TIOVA Inhaler (Tiotropium bromide)
|
|
- Mae Warren
- 6 years ago
- Views:
Transcription
1 Published on: 18 Sep 2014 TIOVA Inhaler (Tiotropium bromide) Composition TIOVA Inhaler Each actuation delivers: Tiotropium Bromide Monohydrate IP equivalent to Tiotropium... 9 mcg Suspended in propellant HFA227...q.s. Dosage Form Inhalation aerosol Pharmacology Pharmacodynamics Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3-receptors at the smooth muscle, leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In pre-clinical in vitro as well as in vivo studies, prevention of methacholine-induced bronchoconstriction effects was dose-dependent and lasted longer than 24 hours. The long duration is probably due to the very slow dissociation from the M3 receptor, exhibiting a significantly longer dissociation half-life than ipratropium. As an N-quaternary anticholinergic, tiotropium bromide is topically (broncho-) selective when administered by inhalation, demonstrating an acceptable therapeutic range before systemic anticholinergic effects may occur. The bronchodilation following inhalation of tiotropium is predominantly a site-specific effect. Dissociation from M2-receptors is faster than from M3, which in functional in vitro studies, elicited (kinetically controlled) receptor subtype selectivity of M3 over M2. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD. Electrophysiology: In a dedicated QT study involving 53 healthy volunteers, tiotropium 18 mcg and 54 mcg (i.e. three times the therapeutic dose) over 12 days did not significantly prolong QT intervals of the ECG. Pharmacokinetics Tiotropium bromide is a non-chiral quaternary ammonium compound and is sparingly soluble in water. In common with other inhaled drugs, the majority of the delivered dose is deposited in the gastrointestinal tract and, to a lesser extent, in the lungs, the intended organ. Many of the pharmacokinetic data described below were obtained with higher doses than recommended for therapy. Absorption Following inhalation by young healthy volunteers, the absolute bioavailability of 19.5% suggests that the fraction
2 reaching the lungs is highly bioavailable. It is expected from the chemical structure of the compound (quaternary ammonium compound) that tiotropium is poorly absorbed from the gastrointestinal tract (10-15%). Food is not expected to influence the absorption of tiotropium for the same reason. Oral solutions of tiotropium have an absolute bioavailability of 2 3%. Maximum tiotropium plasma concentrations were observed 5 7 minutes after inhalation. At steady state, peak tiotropium plasma levels in COPD patients were 12.9 pg/ml and decreased rapidly in a multicompartmental manner. Steady state trough plasma concentrations were 1.71 pg/ml. Distribution Tiotropium shows a volume of distribution of 32 L/kg. The drug is bound by 72% to plasma proteins. Local concentrations in the lungs are not known, but the mode of administration suggests substantially higher concentrations in the lungs. Studies in rats have shown that tiotropium does not readily penetrate the blood-brain barrier. Biotransformation The extent of biotransformation appears to be small. This is evident from a urinary excretion of 74% of unchanged substance after an intravenous dose to young healthy volunteers. Tiotropium, an ester, is non-enzymatically cleaved to the alcohol (N-methylscopine) and dithienylglycolic acid, neither of which binds to muscarinic receptors. In vitro experiments with human liver microsomes and human hepatocytes suggest that that some further drug (< 20% of dose after intravenous administration) is metabolized by cytochrome P450-dependent oxidation and subsequent glutathione conjugation to a variety of Phase II metabolites. In vitro studies using human liver microsomes found that this enzymatic pathway can be inhibited by CYP2D6 and 3A4 inhibitors, such as quinidine, ketoconazole, and gestodene. Thus, CYP2D6 and 3A4 are involved in the metabolic pathway that is responsible for the elimination of a small part of the administered dose. In vitro studies using human liver microsomes showed that tiotropium in supra-therapeutic concentrations does not inhibit CYP1A1, 1A2, 2B6, 2C9, 2C19, 2D6, 2E1, or 3A4. Elimination The effective half-life of tiotropium ranges between hours in COPD patients. After an intravenous dose in young healthy volunteers, total clearance was 880 ml/min. Intravenously administered tiotropium is mainly excreted unchanged in the urine (74%). After inhalation by COPD patients to steady-state, urinary excretion is 7% (1.3 mcg) of the unchanged drug over 24 hours, the remainder being mainly non-absorbed drug in the gut, which is eliminated via the faeces. The renal clearance of tiotropium exceeds the creatinine clearance (CrCl), indicating active secretion into the urine. After continual once-daily inhalation by COPD patients, pharmacokinetic steady state was reached by day 7 with no accumulation thereafter. Special Populations Elderly Patients As expected for drugs predominantly excreted renally, advanced age was associated with a decrease of tiotropium renal clearance (365 ml/min in COPD patients < 65 years to 271 ml/min in COPD patients 65 years), which may be explained by decreased renal function. This did not result in a corresponding increase in AUC 0-6,ss or C max, ss values. Hepatically-impaired Patients Liver insufficiency is not expected to have any relevant influence on tiotropium bromide pharmacokinetics. Tiotropium bromide is predominantly cleared by renal elimination (74% in young healthy volunteers) and simple non-enzymatic ester cleavage to pharmacologically inactive products. Renally-impaired Patients Following once daily inhaled administrations of tiotropium to steady-state in COPD patients, mild renal impairment (CL CR ml/min) resulted in slightly higher AUC 0-6,ss (between % higher) and similar C max, ss values compared to patients with normal renal function(cl CR >80 ml/min). Mild renal impairment (CrCl of ml/min), which is often seen in elderly patients, increased tiotropium plasma
3 concentrations (39% increase in AUC 0 4h after intravenous infusion). In COPD patients with moderate to severe renal impairment (CL CR < 50 ml/min), the intravenous administration of tiotropium resulted in doubling of the total exposure (82% increase in AUC 0 4h and 52% higher Cmax), compared to COPD patients with normal renal function, which was confirmed by plasma concentrations after inhalation. Indication TIOVA Inhaler is indicated in the maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Dosage And Administration The recommended dosage of tiotropium bromide is 2 puffs of TIOVA Inhaler once daily. TIOVA Inhaler may be used with a Zerostat/Zerostat VT Spacer device in patients who find it difficult to synchronize aerosol actuation with inspiration of breath. The recommended dose should not be exceeded. Contraindications TIOVA Inhaler is contraindicated in patients with a history of hypersensitivity to tiotropium, atropine or its derivatives, including ipratropium, or to any component of this product. Warnings And Precautions TIOVA Inhaler is intended as a once-daily maintenance treatment for COPD and are not indicated for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. In the event of an acute attack, a rapid-acting beta 2 -agonist should be used. Immediate hypersensitivity reactions may occur after administration of TIOVA Inhaler. If such a reaction occurs, therapy with TIOVA Inhaler should be stopped at once and alternative treatments should be considered. Given the similar structural formula of atropine to tiotropium, patients with a history of hypersensitivity reactions to atropine should be closely monitored for similar hypersensitivity reactions to TIOVA Inhaler. In addition, TIOVA Inhaler should be used with caution in patients with severe hypersensitivity to milk proteins. Inhaled medicines, including TIOVA Inhaler, may cause paradoxical bronchospasm. If this occurs, treatment with TIOVA Inhaler should be stopped and other treatments considered. Tiotropium should be used with caution in patients with known cardiac rhythm disorders. Tiotropium should be used with caution in patients with recent myocardial infarction < 6 months; any unstable or life threatening cardiac arrhythmia or cardiac arrhythmia requiring intervention or a change in drug therapy in the past year; hospitalisation of heart failure (NYHA Class III or IV) within the past year. These patients were excluded from the clinical trials and these conditions may be affected by the anticholinergic mechanism of action. TIOVA Inhaler should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction. Also in general, patients should be cautioned to avoid getting the drug powder into their eyes. They should be advised that this may result in the precipitation or worsening of narrow-angle glaucoma, eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema. In such a case, patients should stop using TIOVA Inhaler and consult a specialist immediately. Prescribers and patients should be alert for signs and symptoms of prostatic hyperplasia or bladder-neck obstruction (e.g., difficulty passing urine, painful urination). Patients should consult a physician immediately should any of these
4 signs or symptoms develop. As plasma concentration increases with decreased renal function in patients with moderate to severe renal impairment (creatinine clearance 50 ml/min) TIOVA Inhaler should be used only if the expected benefit outweighs the potential risk. There is no long term experience in patients with severe renal impairment. Dry mouth, which has been observed with anti-cholinergic treatment, may in the long term be associated with dental caries. Tiotropium bromide should not be used more frequently than once daily. Drug Interactions Although no formal drug interaction studies have been performed, tiotropium bromide has been used concomitantly with other drugs commonly used in COPD and asthma without clinical evidences of drug interactions. These include sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, anti-ige treatment. Use of LABA or ICS was not found to alter the exposure to tiotropium. The co-administration of tiotropium bromide with other anticholinergic containing drugs has not been studied and therefore is not recommended. Renal impairment Patients with moderate to severe renal impairment (creatinine clearance of 50 ml/min) treated with TIOVA Inhaler should be monitored closely for anticholinergic side effects. Hepatic impairment The effects of hepatic impairment on the pharmacokinetics of tiotropium were not studied. Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses. As a precautionary measure, it is preferable to avoid the use of TIOVA Inhaler during pregnancy. Lactation Clinical data from nursing mothers exposed to tiotropium are not available. Based on studies in lactating rodents, tiotropium is excreted into breast milk only in small amounts. It is not known whether tiotropium is excreted into human milk, but because many drugs are excreted into human milk and given the findings in rats, caution should be exercised if tiotropium bromide is administered to a nursing mother. Paediatric Use TIOVA Inhaler are approved for use in the maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. This disease does not normally occur in children. The safety and effectiveness of tiotropium bromide in paediatric patients have not been established. The efficacy and safety of tiotropium in children and adolescents has not yet been established. Geriatric Use Instances of dry mouth increased with age in patients receiving tiotropium bromide. A higher frequency of constipation and urinary tract infections with increasing age was observed in the tiotropium bromide group in the placebo-controlled studies. No overall differences in effectiveness were observed among various age groups. Based on available data, no adjustment of tiotropium bromide dosage in geriatric patients is warranted.
5 Undesirable Effects Many of the listed undesirable effects can be assigned to the anticholinergic properties of tiotropium. In COPD, the frequencies assigned to the undesirable effects listed below are based on crude incidence rates of adverse drug reactions (i.e. events attributed to tiotropium) observed in the tiotropium group (9,647 patients) from 28 pooled placebocontrolled clinical trials in COPD with treatment periods ranging from four weeks to four years. In patients with COPD, the common ( 1/100 to <1/10) adverse reaction includes dry mouth; the uncommon ( 1/1,000 to <1/100) adverse reactions include dizziness, headache, taste disorders, blurred vision, atrial fibrillation, cough, pharyngitis, dysphonia, constipation, gastroesophageal reflux disease, oropharyngeal candidiasis, rash, dysuria and urinary retention; rare ( 1/10,000 to <1/1,000) adverse reactions include insomnia, glaucoma, increased intraocular pressure, supraventricular tachycardia, tachycardia, palpitations, bronchospasm, epistaxis, laryngitis, sinusitis, intestinal obstruction, including ileus paralytic, gingivitis, glossitis, dysphagia, stomatitis, nausea, urticaria, pruritus, hypersensitivity (including immediate reactions), angioedema and urinary tract infection; not known (cannot be estimated from the available data) adverse reactions include: dehydration, dental caries, anaphylactic reaction, skin infection, skin ulcer, dry skin, joint swelling. In controlled clinical studies, the commonly observed undesirable effects were anticholinergic undesirable effects such as dry mouth which occurred in approximately 4% of patients. In 28 clinical trials, dry mouth led to discontinuation in 18 of 9,647 tiotropium treated patients (0.2%). Serious undesirable effects consistent with anticholinergic effects include glaucoma, constipation and intestinal obstruction including ileus paralytic as well as urinary retention. An increase in anticholinergic effects may occur with increasing age. Overdosage High doses of tiotropium may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 340 mcg of tiotropium in healthy volunteers. Additionally, no relevant adverse effects, beyond dry mouth, were observed following a 7-day dosing of up to 170 mcg of tiotropium bromide in healthy volunteers. In a multiple-dose study in COPD patients with a maximum daily dose of 43 mcg of tiotropium bromide over 4 weeks, no significant undesirable effect has been observed. Acute intoxication by inadvertent oral ingestion of tiotropium bromide is unlikely, since it is not well absorbed systemically. Packinging Information TIOVA Inhaler with Dose Counter. Each canister contains 200 metered doses Last updated: May 2016 Last reviewed: May 2016 TIOVA Inhaler Source URL:
IPRAVENT Respules/Respirator solution (Ipratropium bromide)
Published on: 19 Sep 2014 IPRAVENT Respules/Respirator solution (Ipratropium bromide) Composition IPRAVENT Respules Each 2 ml contains: Ipratropium Bromide BP equivalent to Ipratropium Bromide (anhydrous)
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationSUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006
SUMMARY OF PRODUCT CHARACTERISTICS Version: March 2006 1. NAME OF THE MEDICINAL PRODUCT FAVINT 18 microgram, inhalation powder, hard capsule 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains
More informationDUOVA Rotacaps (Tiotropium bromide monohydrate + Formoterol fumarate dihydrate)
Published on: 10 Jul 2014 DUOVA Rotacaps (Tiotropium bromide monohydrate + Formoterol fumarate dihydrate) Black Box Warning: Asthma-Related Death Long-acting beta 2 -adrenergic agonists (LABA) increase
More informationSPIRIVA RESPIMAT (tiotropium bromide) inhalation spray, for oral inhalation Initial U.S. Approval: 2004
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA RESPIMAT safely and effectively. See full prescribing information for SPIRIVA RESPIMAT. SPIRIVA
More informationNew Zealand Datasheet
New Zealand Datasheet Name of Medicine SPIRIVA RESPIMAT Tiotropium 2.5 mcg Presentation SPIRIVA RESPIMAT 2.5 micrograms/puff, solution for inhalation. Each puff contains tiotropium 2.5 micrograms, equivalent
More informationPRODUCT MONOGRAPH. Tiotropium (as tiotropium bromide monohydrate) Inhalation Solution. 2.5 mcg per actuation
PRODUCT MONOGRAPH Pr SPIRIVA RESPIMAT Tiotropium (as tiotropium bromide monohydrate) Inhalation Solution 2.5 mcg per actuation Bronchodilator Long-Acting Muscarinic Antagonist (LAMA) SPIRIVA RESPIMAT cartridge
More informationTRIOHALE Inhaler (Tiotropium bromide + Formoterol fumarate + Ciclesonide)
Published on: 20 Sep 2014 TRIOHALE Inhaler ( bromide + fumarate + ) Composition TRIOHALE Inhaler Each puff contains: Bromide monohydrate equivalent to...9 mcg Fumarate Dihydrate IP.....6mcg IP...200 mcg
More informationSPIRIVA (tiotropium bromide)
SPIRIVA (tiotropium bromide) NAME OF THE MEDICINE Active ingredient: tiotropium (as tiotropium bromide monohydrate) Chemical name: 3-Oxa-9-azoniatricyclo[3.3.1.0 2,4 ]nonane, 7-[(hydroxydi-2- thienylacetyl)oxy]-9,9-dimethyl-,
More informationChronic obstructive pulmonary disease (COPD) is a progressive,
INFORMATION for the PHARMACIST This article was sponsored by Boehringer Ingelheim Pharmaceuticals, Inc. Improving Lung Function (FEV 1 ) in COPD Through Appropriate Counseling on Use of Inhaled Medications
More information11/2011. Revised: 03/2012 WARNINGS AND PRECAUTIONS Not for acute use: Not for use as a rescue medication (5.1)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA HandiHaler safely and effectively. See full prescribing information for SPIRIVA HandiHaler.
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE DESCRIPTION. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Unit Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationUtibron Neohaler. (indacaterol, glycopyrrolate) New Product Slideshow
Utibron Neohaler (indacaterol, glycopyrrolate) New Product Slideshow Introduction Brand name: Utibron Neohaler Generic name: Indacaterol, glycopyrrolate Pharmacological class: Long-acting beta2- agonist
More informationPRODUCT INFOMATION APO-IPRATROPIUM SOLUTION
PRODUCT INFOMATION APO-IPRATROPIUM SOLUTION NAME OF THE MEDICINE Ipratropium bromide. Chemical Name: (1R,3r,5S,8r)-3-[[(2RS)-3-Hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1- methylethyl)-8-azoniabicyclo[3.2.1]octane
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT Srivasso 18 microgram, inhalatiepoeder in harde capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 22.5 microgram
More informationSUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET
This information is from an international website which is intended for healthcare professionals not located in the United States of America (US) and the United Kingdom (UK). SPIRIVA RESPIMAT is subject
More informationPRODUCT MONOGRAPH SPIRIVA. Tiotropium Capsules for Oral Inhalation (18 μg tiotropium per capsule as tiotropium bromide monohydrate)
PRODUCT MONOGRAPH Pr SPIRIVA Tiotropium Capsules for Oral Inhalation (18 μg tiotropium per capsule as tiotropium bromide monohydrate) Capsules to be used only with the supplied HandiHaler inhalation device
More informationATROVENT Metered Aerosol (CFC-free)
NAME OF THE DRUG ATROVENT Metered Aerosol (CFC-free) Atrovent metered aerosol contains the active ingredient ipratropium bromide. DESCRIPTION Ipratropium bromide is a synthetic quaternary ammonium compound,
More informationPRODUCT INFORMATION. IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE DESCRIPTION PHARMACOLOGY. Ipratropium Bromide BP
PRODUCT INFORMATION IPRAVENT Inhalation Solution Multi Dose NAME OF THE MEDICINE Ipratropium Bromide BP Ipratropium bromide is a quaternary isopropyl derivative of atropine. Its chemical name is (1R, 3r,
More informationSPIRIVA HANDIHALER (tiotropium bromide inhalation powder), for oral inhalation use Initial U.S. Approval: 2004
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SPIRIVA HANDIHALER safely and effectively. See full prescribing information for SPIRIVA HANDIHALER.
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationPRODUCT MONOGRAPH. Tiotropium (as tiotropium bromide monohydrate) and Olodaterol (as olodaterol hydrochloride) Inhalation Solution
PRODUCT MONOGRAPH Pr INSPIOLTO RESPIMAT Tiotropium (as tiotropium bromide monohydrate) and Olodaterol (as olodaterol hydrochloride) Inhalation Solution 2.5 mcg/2.5 mcg per actuation INSPIOLTO RESPIMAT
More information14 41 minutes Vd 218 t ½ 22 to 70 Clearance hours Protein Binding 71%, active metabolite 42% Bioavailability 3%
Brand Name: Yupelri Generic Name: revefenacin Manufacturer: Mylan Drug Class: Anticholinergic Uses: Labeled Uses: inhalation solution for maintenance treatment of COPD 1 Unlabeled Uses: no off-label indications
More informationSpiriva HandiHaler (tiotropium bromide inhalation powder)
ATTENTION PHARMACIST: Detach Patient's Instructions for Use from package insert and dispense with product. Spiriva HandiHaler (tiotropium bromide inhalation powder) FOR ORAL INHALATION ONLY Rx Only Prescribing
More informationATROVENT NASAL and ATROVENT NASAL FORTE PRODUCT INFORMATION
ATROVENT NASAL and ATROVENT NASAL FORTE PRODUCT INFORMATION DESCRIPTION Approved Name Chemical Name Ipratropium bromide (1R, 3r, 5S, 8r)-8-Isopropyl-3-( tropoyloxytropanium bromide. C 20 H 30 NO 3 Br.
More information- COPD treatment - Eklira 400 μg Genuair 30 doses Eklira 400 μg Genuair 60 doses < Inhaled aclidinium bromide>
Kyorin Pharmaceutical Co., Ltd. 1 June 2016 (4nd version) Standard Commodity Classification No. of Japan 872259 Storage Stored at room temperature - COPD treatment - Eklira 400 μg Genuair 30 doses Eklira
More informationPage 1 of 23. Reference ID:
1 HIGHLIGHTS OF PRESCRIBING INFORMATION 38 Paradoxical bronchospasm: Discontinue TUDORZA 2 39 PRESSAIR and consider other treatments if 3 These highlights do not include all the 40 paradoxical bronchospasm
More informationFLOMIST Aqueous Nasal Spray (Fluticasone propionate)
Published on: 10 Jul 2014 FLOMIST Aqueous Nasal Spray (Fluticasone propionate) Composition FLOMIST Aqueous Nasal Spray Each spray delivers: Fluticasone Propionate BP...50 mcg Fluticasone Propionate BP...
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationComposition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate).
VENTOL Composition Each ml of Ventol solution for inhalation contains 5 mg Salbutamol (as sulphate). Respiratory Solution Action Salbutamol is a short-acting, relatively selective beta2-adrenoceptor agonist.
More informationVESIGARD Tablets (Darifenacin hydrobromide)
Published on: 10 Jul 2014 VESIGARD Tablets (Darifenacin hydrobromide) Composition VESIGARD 7.5 Extended Release Tablets Each tablet contains: Darifenacin (as a hydrobromide).. 7.5 mg Dosage Form Tablets
More informationSEROBID Inhaler (Salmeterol xinafoate)
Published on: 10 Jul 2014 SEROBID Inhaler (Salmeterol xinafoate) Composition Each actuation delivers: Salmeterol (as Salmeterol Xinafoate IP) 25 mcg Suspended in propellant HFA 134a.....q.s. Dosage Form
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More information7.2 Part VI.2 Elements for a Public Summary
7.2 Part VI.2 Elements for a Public Summary 7.2.1 Part VI.2.1 Overview of disease epidemiology Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationSTIOLTO RESPIMAT (tiotropium bromide and olodaterol) inhalation spray, for oral inhalation use Initial U.S. Approval: 2015
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use STIOLTO RESPIMAT safely and effectively. See full prescribing information for STIOLTO RESPIMAT. STIOLTO
More informationAtrovent HFA (ipratropium bromide HFA) Inhalation Aerosol
ATTENTION PHARMACIST: Detach "Patient's Instructions for Use" from package insert and dispense with the product. Atrovent HFA (ipratropium bromide HFA) Inhalation Aerosol For Oral Inhalation Only Rx only
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Version: February (MRP variation number: NL/H/299/001/II/033 and NL/H/299/001/II/034)
SUMMARY OF PRODUCT CHARACTERISTICS Version: February 2008 (MRP variation number: NL/H/299/001/II/033 and NL/H/299/001/II/034) 1 1. NAME OF THE MEDICINAL PRODUCT SPIRIVA 18 microgram, inhalation powder,
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationDUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 19 Sep 2014 DUOLIN Rotacaps (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Rotacaps Each capsule contains: Levosalbutamol sulphate 100 mcg Ipratropium bromide.. 40 mcg
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationMTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride
MTnL Tablet/ MTnL Kid Tablet Montelukast & Levocetirizine dihydrochloride COMPOSITION MTnL Tablets Each film-coated tablet contains: Montelukast sodium equivalent to montelukast Levocetirizine dihydrochloride
More informationASTHALIN Respirator Solution (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respirator Solution (Salbutamol sulphate) Composition Each 1 ml contains: Salbutamol Sulphate IP equivalent to Salbutamol IP.. 5 mg Dosage Form Solution for inhalation
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationNEW ZEALAND DATA SHEET SEREVENT Accuhaler
NEW ZEALAND DATA SHEET SEREVENT Accuhaler Salmeterol xinafoate (50 mcg per inhalation) Presentation SEREVENT Accuhaler is a moulded plastic device containing a foil strip with 60 regularly placed blisters
More informationOXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA
10-14 OXIS TURBUHALER 4.5 µg/dose and 9 µg/dose ASTRAZENECA formoterol fumarate dihydrate Inhalation powder Composition Each delivered dose (i.e. the dose leaving the mouthpiece) from Oxis Turbuhaler contains
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi)
Core Safety Profile Active substance: Budesonide Pharmaceutical form(s)/strength: Dry Powder Inhaler, Nebuliser Suspension, pressurised Metered Dose Inhaler (pmdi) P - RMS: DK/H/PSUR/0041/001 Date of FAR:
More informationVENTOLIN RESPIRATOR SOLUTION
VENTOLIN RESPIRATOR SOLUTION Salbutamol QUALITATIVE AND QUANTITATIVE COMPOSITION VENTOLIN Respirator Solution contains 5mg salbutamol, as sulphate, per ml of solution and is supplied in 10 ml bottles.
More informationPRUCAPLA Tablets (Prucalopride)
Published on: 2 May 2018 PRUCAPLA Tablets (Prucalopride) Composition PRUCAPLA 1 mg Each film coated tablet contains: Prucalopride succinate equivalent to Prucalopride 1 mg Excipients. q. s. Color: Titanium
More informationSummary of Product Characteristics
1 NAME OF THE MEDICINAL PRODUCT Summary of Product Characteristics Combivent UDVs 500 micrograms/2.5mg per 2.5ml Nebuliser Solution 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 2.5ml single dose unit
More informationINSPRA 25 & 50 mg TABLETS
INSPRA 25 & 50 mg TABLETS SCHEDULING STATUS: Schedule 4 PROPRIETARY NAMES (and dosage forms): INSPRA 25 (Tablets) INSPRA 50 (Tablets) COMPOSITION: INSPRA 25: INSPRA 50: Each tablet contains 25 mg eplerenone
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ebateva 10 mg Orodispersible Tablets Ebateva 20 mg Orodispersible Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One orodispersible
More informationPRODUCT MONOGRAPH. Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules. 110 mcg/50 mcg per capsule
PRODUCT MONOGRAPH Pr ULTIBRO BREEZHALER Indacaterol (as maleate)/glycopyrronium (as bromide) inhalation powder hard capsules 110 mcg/50 mcg per capsule ULTIBRO BREEZHALER capsules to be used only with
More informationCOMBIVENT Metered Aerosol Boehringer
COMBIVENT Metered Aerosol Boehringer Composition 1 metered dose contains: (8r)-3*-Hydroxy-8-isopropyl-1*,5*-tropanium bromide (±)-tropate monohydrate (= ipratropium bromide monohydrate) 21 mcg equivalent
More informationPRODUCT INFORMATION BRETARIS GENUAIR
PRODUCT INFORMATION BRETARIS GENUAIR NAME OF THE MEDICINE aclidinium bromide Chemical Structure Stereochemistry: Chemical name (IUPAC): INN: The product has one optically active centre. Aclidinium bromide
More informationAUSTRALIAN PRODUCT INFORMATION BRETARIS GENUAIR (ACLIDINIUM BROMIDE)
AUSTRALIAN PRODUCT INFORMATION BRETARIS GENUAIR (ACLIDINIUM BROMIDE) 1. NAME OF THE MEDICINE aclidinium bromide 2. QUALITATIVE AND QUANTITATIVE COMPOSITION BRETARIS GENUAIR 322 micrograms inhalation powder
More informationALFUSIN Tablets (Alfuzosin hydrochloride)
Published on: 20 Sep 2014 ALFUSIN Tablets (Alfuzosin hydrochloride) Composition Each film-coated extended-release tablet contains: Alfuzosin hydrochloride Ph.Eur... 10 mg Dosage Form Extended-release tablet
More informationAtrovent Administration
Atrovent Administration ICEMA Training 2007 Sherri Shimshy RN OBJECTIVES Describe the pharmacology of Atrovent Identify the indications for use of Atrovent in the Adult Population Identify the indications
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA. INCRUSE
More informationDUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide)
Published on: 10 Jul 2014 DUOLIN Respules (Levosalbutamol sulphate + Ipratropium bromide) Composition DUOLIN Respules Each 2.5 ml unit-dose vial contains: Levosalbutamol sulphate.1.25 mg Ipratropium bromide
More informationASTHALIN Respules (Salbutamol sulphate)
Published on: 28 Jan 2016 ASTHALIN Respules (Salbutamol sulphate) Composition Each 2.5 ml respule contains: Salbutamol Sulphate IP equivalent to Salbutamol IP. 2.5 mg Normal saline solution.q.s. Dosage
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Telfast 120 mg film-coated tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 120 mg of fexofenadine hydrochloride,
More informationFURAMIST Nasal Spray (Fluticasone furoate )
Published on: 21 Jan 2016 FURAMIST Nasal Spray (Fluticasone furoate ) Composition Each spray contains: Fluticasone furoate 27.5 mcg Dosage Form Aqueous intranasal spray Pharmacology Pharmacodynamics Fluticasone
More informationHistory & Development
RSPT 2317 Anticholinergic Bronchodilators () History & Development Prototypical parasympatholytic agent is atropine an alkaloid found naturally in the plants Atropa belladona (nightshade) and Datura species
More informationPRODUCT INFORMATION VENTOLIN DISKS
PRODUCT INFORMATION VENTOLIN DISKS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4 parts
More informationCEDIAMATE Metformin Tablets USP 500 mg
CEDIAMATE Metformin Tablets USP 500 mg COMPOSITION: Cediamate Each un-coated tablet contains: Metformin Hydrochloride USP Excipients 500 mg Q.S PHARMACOLOGY: Pharmacotherapeutic group: Blood Glucose lowering
More informationRESPIRATORY PHARMACOLOGY - ASTHMA. Primary Exam Teaching - Westmead ED
RESPIRATORY PHARMACOLOGY - ASTHMA Primary Exam Teaching - Westmead ED Sympathomimetic agents MOA: relax airway smooth muscle and inhibit broncho constricting mediators from mast cells May also inhibit
More informationPRODUCT INFORMATION INTAL CFC-FREE INHALER AND INTAL FORTE CFC-FREE INHALER
PRODUCT INFORMATION INTAL CFC-FREE INHALER AND INTAL FORTE CFC-FREE INHALER NAME OF MEDICINE Sodium Cromoglycate for Oral Inhalation. C 23 H 14 Na 2 O 11 Mol Wt. 512.3 CAS No. [15826-37-6] Sodium cromoglycate
More informationChapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 7 Anticholinergic (Parasympatholytic) Bronchodilators Clinical Indications for Use Indication for anticholinergic bronchodilator COPD maintenance Indication for combined anticholinergic and β-agonist
More informationProduct Monograph. Published by
Product Monograph Published by INDICATION SPIRIVA HandiHaler and SPIRIVA RESPIMAT are indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive
More informationCOPD Respiratory Antimuscarinics Drug Class Monograph
Line of Business: Medi-Cal Effective Date: May 17, 2017 Revision Date: May 17, 2017 COPD Respiratory Antimuscarinics Drug Class Monograph This policy has been developed through review of medical literature,
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationReference ID: Page 1
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use COMBIVENT RESPIMAT safely and effectively. See full prescribing information for COMBIVENT RESPIMAT.
More informationMonocast Description Indications
Monocast Tablet Description The active ingredient of Monocast tablet is Montelukast Sodium INN. Montelukast is a selective and orally active leukotriene receptor antagonist that inhibits the cysteinyl
More informationSUMMARY OF PRODUCT CHARACTERISTICS 2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Fexofenadine hydrochloride 180 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 180mg
More informationOXYSPAS Tablets (Oxybutynin chloride)
Published on: 10 Jul 2014 OXYSPAS Tablets (Oxybutynin chloride) Composition OXYSPAS-2.5 Tablets Each uncoated tablet contains Oxybutynin chloride... 2.5 mg OXYSPAS-5 Tablets Each uncoated tablet contains
More informationSummary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate)
EMA/605453/2014 Summary of the risk management plan (RMP) for Duaklir Genuair (aclidinium / formoterol fumarate dihydrate) This is a summary of the risk management plan (RMP) for Duaklir Genuair, which
More informationVersion 3.0, 04/2013 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET. Version: 9 Mar 2018
Version 3.0, 04/2013 SUMMARY OF PRODUCT CHARACTERISTICS, LABELLING AND PACKAGE LEAFLET Version: 9 Mar 2018 1 SUMMARY OF PRODUCT CHARACTERISTICS Version: 9 Mar 2018 2 1. NAME OF THE MEDICINAL PRODUCT Spiriva
More information2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Summary of Product Characteristics 1. NAME OF THE MEDICINAL PRODUCT {To be completed nationally} 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 1 mg tablets: each tablet contains 1 mg granisetron (as hydrochloride).
More informationPRODUCT MONOGRAPH DUAKLIR GENUAIR
PRODUCT MONOGRAPH DUAKLIR GENUAIR aclidinium bromide/formoterol fumarate dihydrate inhalation powder 400 mcg / 12 mcg Bronchodilator Combination Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting
More informationAEROCORT Inhaler (Beclomethasone dipropionate + Levosalbutamol)
Published on: 28 Jan 2016 AEROCORT Inhaler ( + ) Composition Each actuation delivers: IP. 50 mcg sulphate IP equivalent to levosalbutamol..50 mcg Suspended in propellant HFA-134a.. q.s. Dosage Form Inhalation
More informationINCRUSE ELLIPTA PRODUCT INFORMATION
INCRUSE ELLIPTA PRODUCT INFORMATION NAME OF THE MEDICINE Umeclidinium (as bromide) Structure of umeclidinium bromide: OH N O Br Chemical Name: The chemical name of umeclidinium bromide is 1- Azoniabicyclo[2.2.2]octane,
More informationMigraleve, Migraleve Pink and Migraleve Yellow Product Information
Migraleve, Migraleve Pink and Migraleve Yellow Product Information Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard Adverse events should also
More informationIMPORTANT: PLEASE READ
IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION Pr Spiriva Respimat Tiotropium Bromide Monohydrate Inhalation Solution Read this carefully before you start taking SPIRIVA RESPIMAT and each time you
More informationDUONASE Nasal Spray (Azelastine hydrochloride + Fluticasone propionate)
Published on: 10 Jul 2014 DUONASE Nasal Spray (Azelastine hydrochloride + Fluticasone propionate) Composition DUONASE Nasal Spray Each spray delivers: Azelastine Hydrochloride BP 140 mcg Fluticasone Propionate
More informationPRODUCT INFORMATION VENTOLIN ROTACAPS
PRODUCT INFORMATION VENTOLIN ROTACAPS APPROVED NAME: Salbutamol sulphate B.P. PHYSICAL AND CHEMICAL CHARACTERISTICS: Salbutamol sulphate is a white or almost white odourless powder. It is soluble in 4
More informationFarmadol. Paracetamol 10 mg/ml INFUSION SOLUTION
Farmadol Paracetamol 10 mg/ml INFUSION SOLUTION Composition Each ml contains: Paracetamol 10 mg Pharmacology Pharmacodynamic properties The precise mechanism of the analgesic and antipyretic properties
More informationPRODUCT INFORMATION TILADE CFC-FREE
NAME OF THE MEDICINE nedocromil sodium PRODUCT INFORMATION TILADE CFC-FREE DESCRIPTION Tilade CFC-Free contains nedocromil sodium as a suspension in a non-cfc propellant, 1,1,1,2,3,3,3-heptafluoropropane
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET NAME OF MEDICINE OXIS TURBUHALER Eformoterol fumarate dihydrate (6 µg per inhalation) PRESENTATION OXIS TURBUHALER is a multidose, inspiratory flow driven, metered dose, dry powder
More informationPARACOD Tablets (Paracetamol + Codeine phosphate)
Published on: 22 Sep 2014 PARACOD Tablets (Paracetamol + Codeine phosphate) Composition PARACOD Tablets Each effervescent tablet contains: Paracetamol IP...650 mg Codeine Phosphate IP... 30 mg Dosage Form/s
More information